Management of chronic asthma: In adults

Asthma and COPD

Volumn , Issue , 2009, Pages 761-774

  Pascual, Rodolfo M ^a   Peters, Stephen P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882844855     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374001-4.00063-8     Document Type: Chapter

References (80)

1. National Asthma Education and Prevention Program, Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma. 2007; Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD.
2. Global Strategy for Asthma Management and Prevention, Available from:. http://www.ginasthma.org.
3. Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST Real-world evaluation of asthma control and treatment (REACT): Findings from a national web-based survey. J Allergy Clin Immunol 2007.
4. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir. Crit Care Med 2004, 836-844.
5. Miller MK, Lee JH, Miller DP, Wenzel SE Recent asthma exacerbations: A key predictor of future exacerbations. Respir Med 2006.
6. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, Dimango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Israel E Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2007, 228-234.
7. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007, 2027-2039.
8. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991, 388-392.
9. Rafferty P, Tucker LG, Frame MH, Fergusson RJ, Biggs BA, Crompton GK Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: Assessment of relative prednisolone-sparing effects. Br J Dis Chest 1985, 244-250.
10. Stempel DA, StoloffSW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP Adherence to asthma controller medication regimens. Respir Med 2005, 1263-1267.
11. StoloffSW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004, 245-251.
12. Richter K, Janicki S, Jorres RA, Magnussen H Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J 2002, 865-871.
13. Spooner CH, Saunders LD, Rowe BH Nedocromil sodium for preventing exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2002, CD001183.
14. LeffJA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998, 147-152.
15. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel E Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005, 1519-1528.
16. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007, 2040-2052.
17. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 129-136.
18. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A, Hensley MJ, Walters EH Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003, CD001117.
19. Gibson PG, Powell H, Coughlan J, Wilson AJ, Hensley MJ, Abramson M, Bauman A, Walters EH Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev 2002, CD001005.
20. Bailey WC, Richards JM, Brooks CM, Soong SJ, Windsor RA, Manzella BA A randomized trial to improve self-management practices of adults with asthma. Arch Intern Med 1990, 1664-1668.
21. Wilson SR, Scamagas P, German DF, Hughes GW, Lulla S, Coss S, Chardon L, Thomas RG, Starr-Schneidkraut N, Stancavage FB A controlled trial of two forms of self-management education for adults with asthma. Am J Med 1993, 564-576.
22. Abramson MJ, Puy RM, Weiner JM Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995, 969-974.
23. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993, 6-15.
24. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 1529-36, 2001.
25. Cates CJ, Jefferson TO, Bara AI, Rowe BH Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2004, CD000364.
26. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 1-42.
27. National Asthma Education Program, Expert Panel Report 2, Guidelines for the Diagnosis and Management of Asthma. 1997;.
28. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJ Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001, 2583-2593.
29. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000, 332-336.
30. Lanes SF, Garcia Rodriguez LA, Huerta C Respiratory medications and risk of asthma death. Thorax 2002, 683-686.
31. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, Dolovich M, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lazarus SC, Lemanske RF, Mauger E, Peters SP, Sorkness CA Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002, 410-418.
32. Mjaanes CM, Whelan GJ, Szefler SJ Corticosteroid therapy in asthma: Predictors of responsiveness. Clin Chest Med 2006, 119-132. vii.
33. Greening AP, Ind PW, Northfield M, Shaw G Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen and Hanburys Limited UK Study Group. Lancet 1994, 219-224.
34. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters SP, Spahn JD, Szefler SJ Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. JAMA 2001, 2594-2603.
35. Woolcock A, Lundback B, Ringdal N, Jacques LA Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir. Crit Care Med 1996, 1481-1488.
36. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999, 1862-1868.
37. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJA comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997, 1412-1418.
38. Gross NJ Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006, 36-39.
39. O'Connor BJ, Towse LJ, Barnes PJ Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996, 876-880.
40. Spooner CH, Saunders LD, Rowe BH Nedocromil sodium for preventing exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2002, CD001183.
41. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N EnglJ Med 1054-63, 2000.
42. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997, 887-891.
43. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, Seidenberg BC, Reiss TF Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999, 487-495.
44. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, Gormley GJ, Pearlman DS Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000, 97-104.
45. Lofdahl CG, Reiss TF, LeffJA, Israel E, Noonan MJ, Finn AF, Seidenberg BC, Capizzi T, Kundu S, Godard P Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999, 87-90.
46. Robinson DS, Campbell D, Barnes PJ Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial. Lancet 2001, 2007-2011.
47. Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, Valencia A, Verea H, Viejo JL, Villasante C, Gonzalez-Esteban J, Picado C Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003, 204-210.
48. Beasley R The pulmonary complications of oesophageal disease. Br J Dis Chest 1960, 342-348.
49. ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH, Rabe KF, Bel EH Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005, 812-818.
50. Wu De Nan, Tanifuji Yukio, Kobayashi Hitoshi, Yamauchi Kohei, Kato Chieko, Suzuki Kazuyuki, Inoue Hiroshi Effects of esophageal acid perfusion on airway hyperresponsiveness in patients with bronchial asthma. Chest 2000, 1553-1556.
51. Lazenby JP, Guzzo MR, Harding SM, Patterson PE, Johnson LF, Bradley LA Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest 2002, 625-634.
52. Sontag SJ, O'Connell S, Khandelwal S, Greenlee H, Schnell T, Nemchausky B, Chejfec G, Miller T, Seidel J, Sonnenberg A Asthmatics with gastroesophageal reflux. Long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003, 987-999.
53. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001, 2331-2338.
54. Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS, Ekelund J, Illueca M, Beckman O, Sostek MB Effects of esomeprazole 40mg twice daily on asthma: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2006, 1091-1097.
55. Newman LJ, Platts-Mills TA, Phillips CD, Hazen KC, Gross CW Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia. JAMA 1994, 363-367.
56. Ford ES The epidemiology of obesity and asthma. J Allergy Clin Immunol 2002, 897-909.
57. Sin DD, Jones RL, Man SF Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002, 1477-1481.
58. Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest 2002, 1256-1263.
59. Hakala K, Stenius-Aarniala B, Sovijarvi A Effects of weight loss on peak flow variability, airways obstruction, and lung volumes in obese patients with asthma. Chest 2000, 1315-1321.
60. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000, 827-832.
61. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 302-308.
62. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 184-190.
63. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ Treatment of allergic asthma with monoclonal anti-IgE antibody. RhuMAb-E25 Study Group. N Engl J Med 1999, 1966-1973.
64. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della CG The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 254-261.
65. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004, 1378-1386.
66. Richeldi L, Ferrara G, Fabbri L, Lasserson T, Gibson P, Richeldi L Macrolides for chronic asthma. Cochrane Database Syst Rev 2005, CD002997.
67. Kraft M, Cassell GH, Pak J, Martin RJ Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest 2002, 1782-1788.
68. Shinkai Masaharu Rubin, Bruce K Macrolides and airway inflammation in children. Paediat Respir Rev 2005, 227-235.
69. Evans DJ, Cullinan P, Geddes DM Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001, CD002985.
70. Alexander AG, Barnes NC, Kay AB Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992, 324-328.
71. Evans DJ, Cullinan P, Geddes DM Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001, CD002993.
72. Schwarz YA, Kivity S, Ilfeld DN, Schlesinger M, Greif J, Topilsky M, Garty MSA clinical and immunologic study of colchicine in asthma. J Allergy Clin Immunol 1990, 578-582.
73. Fish JE, Peters SP, Chambers CV, McGeady SJ, Epstein KR, Boushey HA, Cherniack RM, Chinchilli VM, Drazen JM, Fahy JV, Hurd SS, Israel E, Lazarus SC, Lemanske RF, Martin RJ, Mauger EA, Sorkness C, Szefler SJ An evaluation of colchicine as an alternative to inhaled corticosteriods in moderate asthma. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Am J Respir Crit Care Med 1997, 1165-1171.
74. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 2144-2148.
75. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 1012-1018.
76. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord I Evidence of a role of tumor necrosis factor {alpha} in refractory asthma. N Engl J Med 2006, 697-708.
77. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT The effects of a monoclonal antibody directed against tumor necrosis factor-{alpha} in asthma. Am J Respir Crit Care Med 2006, 753-762.
78. McFadden ER, Warren EL Observations on asthma mortality. Ann Intern Med 1997, 142-147.
79. Rodrigo GJ, Rodrigo C Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 2003, 1908-1915.
80. Rodrigo GJ, Rodrigo C First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000, 1862-1868.